Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.4 USD | +2.27% | -5.18% | +29.19% |
05-07 | AstraZeneca target raised; Antofagasta lowered | AN |
05-03 | AIB GROUP : Stronger revenue growth and a benign cost of risk |
Sales 2024 * | 4.56B 4.91B 385B | Sales 2025 * | 4.34B 4.67B 367B | Capitalization | 12.34B 13.29B 1,044B |
---|---|---|---|---|---|
Net income 2024 * | 1.76B 1.9B 149B | Net income 2025 * | 1.56B 1.68B 132B | EV / Sales 2024 * | 2.71 x |
Net cash position 2024 * | - 0 0 | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | 2.84 x |
P/E ratio 2024 * |
7.11
x | P/E ratio 2025 * |
7.4
x | Employees | 10,551 |
Yield 2024 * |
5.89% | Yield 2025 * |
6.25% | Free-Float | 68.01% |
Latest transcript on AIB Group plc
1 day | +2.27% | ||
1 week | -5.18% | ||
Current month | -5.18% | ||
1 month | +4.45% | ||
3 months | +9.20% | ||
6 months | +27.06% | ||
Current year | +29.19% |
Managers | Title | Age | Since |
---|---|---|---|
Colin Hunt
CEO | Chief Executive Officer | 54 | 31/12/15 |
Donal Galvin
DFI | Director of Finance/CFO | 50 | 31/08/13 |
Graham Fagan
CTO | Chief Tech/Sci/R&D Officer | - | 18/10/23 |
Members of the board | Title | Age | Since |
---|---|---|---|
James Pettigrew
CHM | Chairman | 65 | 27/10/21 |
Basil Geoghegan
BRD | Director/Board Member | - | 03/09/19 |
Colin Hunt
CEO | Chief Executive Officer | 54 | 31/12/15 |
Date | Price | Change | Volume |
---|---|---|---|
06/06/24 | 5.4 | +2.27% | 12,638 |
05/06/24 | 5.28 | -0.56% | 1,925 |
Delayed Quote OTC Markets, June 06, 2024 at 05:07 pm
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+17.35% | 574B | |
+17.82% | 311B | |
+13.87% | 254B | |
+18.71% | 184B | |
+24.83% | 172B | |
+9.14% | 163B | |
+9.11% | 150B | |
-8.66% | 143B | |
+10.82% | 138B |
- Stock Market
- Equities
- A5G Stock
- AIBRF Stock